Cevec Pharmaceuticals announced the launch of the ELEVECTA platform, a technology that enables the large-scale manufacture of adeno-associated virus (AAV) vectors by producing fully stable producer cell lines. The technology is paten protected and is now commercially available for gene therapy programs in late research stages as well as all clinical phases.
The ELEVECTA technology takes a unique approach based on producer cell lines, which have all the necessary elements for AAV production stably integrated in one cell. Up to now, manufacturing of AAV—the most widely used vector for in-vivo gene therapy—has required expensive transfection reagents and cGMP-grade plasmids.
